This finding is consistent with prior studies that demonstrate better outcomes related to CXCL10 expression and support the hypothesis of inhibiting the tumor progression, where individuals with high CXCL10 levels have a low risk for ovarian cancer progression (Bronger et al., 2016; Au et al., 2017). This evidence concerns the gene CXCL10 and ovarian carcinoma.